NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment of diabetic peripheral neuropathy (DPN), announced that it had entered into an agreement with Omron Healthcare Co.
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment of diabetic peripheral neuropathy (DPN), today reported business and financial highlights for the first quarter ended March 31, 2013.
NeuroMetrix has a one year low of $1.98 and a one year high of $5.10. The stock's 50-day moving average is currently $2.31. The company's market cap is $4.5 million.
Company Name Last PVUS$1000 [1Wk] Kips Bay Medical, Inc. (KIPS) US$1.37 895 NeuroMetrix, Inc. (NURO) US$1.98 904 Derma Sciences (DSCI) US$10.94 919 Synergetics USA, Inc. (SURG) US$3.0 935 Hologic, Inc. (HOLX) US$20.25 952.
Company Name Last PVUS$1000 [1Wk] Delcath Systems, Inc. (DCTH) 83.0c 512 NeuroMetrix, Inc. (NURO) US$1.96 879 Synergetics USA, Inc. (SURG) US$2.94 926 THERMOGENESIS Corp.
Company Name Last PVUS$1000 [1Wk] NeuroMetrix, Inc. (NURO) US$1.97 900 Kips Bay Medical, Inc. (KIPS) US$1.38 902 Synergetics USA, Inc. (SURG) US$2.98 928 Spherix Incorporated (SPEX) US$7.54 958 Hologic, Inc. (HOLX) US$20.43 961 ...
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.